1. Home
  2. IVA vs KELYB Comparison

IVA vs KELYB Comparison

Compare IVA & KELYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IVA
  • KELYB
  • Stock Information
  • Founded
  • IVA 2011
  • KELYB 1946
  • Country
  • IVA France
  • KELYB United States
  • Employees
  • IVA N/A
  • KELYB N/A
  • Industry
  • IVA Biotechnology: Pharmaceutical Preparations
  • KELYB Professional Services
  • Sector
  • IVA Health Care
  • KELYB Consumer Discretionary
  • Exchange
  • IVA Nasdaq
  • KELYB Nasdaq
  • Market Cap
  • IVA 359.6M
  • KELYB 426.3M
  • IPO Year
  • IVA 2020
  • KELYB N/A
  • Fundamental
  • Price
  • IVA $2.97
  • KELYB $12.94
  • Analyst Decision
  • IVA Strong Buy
  • KELYB
  • Analyst Count
  • IVA 4
  • KELYB 0
  • Target Price
  • IVA $10.50
  • KELYB N/A
  • AVG Volume (30 Days)
  • IVA 15.3K
  • KELYB 793.0
  • Earning Date
  • IVA 09-24-2025
  • KELYB 08-07-2025
  • Dividend Yield
  • IVA N/A
  • KELYB 2.32%
  • EPS Growth
  • IVA N/A
  • KELYB N/A
  • EPS
  • IVA N/A
  • KELYB N/A
  • Revenue
  • IVA $14,591,573.00
  • KELYB $4,451,600,000.00
  • Revenue This Year
  • IVA $15.38
  • KELYB $8.06
  • Revenue Next Year
  • IVA $24.22
  • KELYB $4.08
  • P/E Ratio
  • IVA N/A
  • KELYB N/A
  • Revenue Growth
  • IVA N/A
  • KELYB N/A
  • 52 Week Low
  • IVA $1.53
  • KELYB $11.04
  • 52 Week High
  • IVA $4.05
  • KELYB $22.16
  • Technical
  • Relative Strength Index (RSI)
  • IVA 38.99
  • KELYB 56.83
  • Support Level
  • IVA $3.12
  • KELYB $12.27
  • Resistance Level
  • IVA $3.61
  • KELYB $13.95
  • Average True Range (ATR)
  • IVA 0.24
  • KELYB 0.29
  • MACD
  • IVA -0.01
  • KELYB 0.08
  • Stochastic Oscillator
  • IVA 13.95
  • KELYB 46.50

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

About KELYB Kelly Services Inc. Class B

Kelly Services Inc is a provider of workforce solutions and consulting, and staffing services. The company's operations are divided into four business segments, namely Professional & Industrial, Science, Education, Outsourcing & Consulting Group, and International. Other than OCG, each segment delivers talent through staffing services, permanent placement, or outcome-based services. OCG segment delivers talent solutions, including managed service providers, payroll process outsourcing, recruitment process outsourcing, and talent advisory services. International also delivers RPO talent solutions within its local markets. The majority of revenue is derived from Professional & Industrial.

Share on Social Networks: